-
EP3256160
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3256160
| EP3256160 - STABLE LIQUID FORMULATION FOR MONOCLONAL ANTIBODIES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 14.06.2019 Database last updated on 24.08.2024 | |
| Former | Examination is in progress Status updated on 21.09.2018 | ||
| Former | Request for examination was made Status updated on 17.11.2017 | ||
| Former | The international publication has been made Status updated on 18.08.2017 | Most recent event Tooltip | 14.06.2019 | Application deemed to be withdrawn | published on 17.07.2019 [2019/29] | Applicant(s) | For all designated states SANOFI 54, rue La Boétie 75008 Paris / FR | [2017/51] | Inventor(s) | 01 /
BUSSEMER, Till Sanofi-Aventis Deutschland GmbH Patent Department 65926 Frankfurt / DE | 02 /
PIEPER, Annette Sanofi-Aventis Deutschland GmbH Patent Department 65926 Frankfurt / DE | 03 /
SAGI, Dijana Sanofi-Aventis Deutschland GmbH Patent Department 65926 Frankfurt / DE | 04 /
STREBE, Nina Sanofi-Aventis Deutschland GmbH Patent Department 65926 Frankfurt / DE | 05 /
YOUSSEFF, Ahmed Sanofi-Aventis Deutschland GmbH Patent Department 65926 Frankfurt / DE | [2017/51] | Representative(s) | Sanofi Patent Department 46 avenue de la Grande Armée 75017 Paris / FR | [N/P] |
| Former [2017/51] | Bouvet, Philippe, et al Sanofi Département Brevets 54, rue La Boétie 75008 Paris / FR | Application number, filing date | 16704440.3 | 12.02.2016 | [2017/51] | WO2016EP53068 | Priority number, date | EP20150305218 | 13.02.2015 Original published format: EP 15305218 | [2017/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016128564 | Date: | 18.08.2016 | Language: | EN | [2016/33] | Type: | A1 Application with search report | No.: | EP3256160 | Date: | 20.12.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 18.08.2016 takes the place of the publication of the European patent application. | [2017/51] | Search report(s) | International search report - published on: | EP | 18.08.2016 | Classification | IPC: | A61K39/395, C07K16/24 | [2017/51] | CPC: |
A61K39/39591 (EP,KR,US);
A61K47/02 (US);
A61K47/12 (US);
A61K47/183 (EP,US);
A61K47/22 (US);
A61K47/26 (EP,US);
A61K9/0019 (EP,US);
A61K9/08 (EP,US);
A61P1/04 (EP);
A61P17/06 (EP);
A61P19/00 (EP);
A61P19/02 (EP);
A61P29/00 (EP);
C07K16/241 (EP,KR,US);
C07K16/2866 (EP,KR,US);
C07K2317/94 (EP,KR,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/51] | Title | German: | STABILE FLÜSSIGKEITSFORMULIERUNG FÜR MONOKLONALE ANTIKÖRPER | [2017/51] | English: | STABLE LIQUID FORMULATION FOR MONOCLONAL ANTIBODIES | [2017/51] | French: | FORMULATION LIQUIDE STABLE POUR DES ANTICORPS MONOCLONAUX | [2017/51] | Entry into regional phase | 13.09.2017 | National basic fee paid | 13.09.2017 | Designation fee(s) paid | 13.09.2017 | Examination fee paid | Examination procedure | 17.08.2017 | Date on which the examining division has become responsible | 13.09.2017 | Examination requested [2017/51] | 21.03.2018 | Amendment by applicant (claims and/or description) | 25.09.2018 | Despatch of a communication from the examining division (Time limit: M04) | 06.02.2019 | Application deemed to be withdrawn, date of legal effect [2019/29] | 07.03.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2019/29] | Fees paid | Renewal fee | 14.02.2018 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 28.02.2019 | 04 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI]WO2014039903 (COHERUS BIOSCIENCES INC [US]) [X] 1-6,9-14,17,24-30 * page 17 - page 26 * [I] 7,8,15,16,18-23; | [XI]WO2006044908 (GENENTECH INC [US], et al) [X] 1,2,4-6,9,10,26-30 * page 40 - page 42 * [I] 3,7,8,11-25; | [XI] - SAMPATHKUMAR KRISHNAN ET AL, Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals; Chapter 16: DEVELOPMENT OF FORMULATIONS FOR THERAPEUTIC MONOCLONAL ANTIBODIES AND Fc FUSION PROTEINS, FORMULATION AND PROCESS DEVELOPMENT STRATEGIES FOR MANUFACTURING BIOPHARMACEUTICALS, JOHN WILEY & SONS, INC, HOBOKEN, N.J, PAGE(S) 383 - 427, (20100805), ISBN 978-0-470-11812-2, XP002712418 [X] 1-10,26-30 * table 16.1 * [I] 11-25 DOI: http://dx.doi.org/10.1002/9780470595886.ch16 |